Laboratory Corporation of America Holdings (LH) Given “Hold” Rating at Robert W. Baird

Robert W. Baird reiterated their hold rating on shares of Laboratory Corporation of America Holdings (NYSE:LH) in a research note published on Tuesday morning. The firm currently has a $166.00 price objective on the medical research company’s stock.

Several other brokerages have also recently weighed in on LH. Craig Hallum restated a buy rating and set a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a sell rating to a hold rating in a report on Thursday, July 27th. Barclays PLC boosted their target price on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an overweight rating in a report on Thursday, July 27th. Jefferies Group LLC restated a hold rating and set a $170.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Wednesday, September 13th. Finally, ValuEngine upgraded Laboratory Corporation of America Holdings from a hold rating to a buy rating in a report on Wednesday, September 6th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Laboratory Corporation of America Holdings has an average rating of Buy and an average target price of $170.31.

Shares of Laboratory Corporation of America Holdings (LH) traded down 0.05% during midday trading on Tuesday, reaching $149.65. The company’s stock had a trading volume of 94,192 shares. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22. The firm has a market cap of $15.23 billion, a price-to-earnings ratio of 20.96 and a beta of 0.92. The stock’s 50 day moving average price is $153.32 and its 200 day moving average price is $148.94.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The business had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.36 EPS. Analysts predict that Laboratory Corporation of America Holdings will post $9.52 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/10/18/laboratory-corporation-of-america-holdings-lh-given-hold-rating-at-robert-w-baird.html.

In other Laboratory Corporation of America Holdings news, CEO David P. King sold 44,687 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $156.86, for a total value of $7,009,602.82. Following the sale, the chief executive officer now owns 258,753 shares of the company’s stock, valued at $40,587,995.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Glenn A. Eisenberg sold 5,968 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total value of $951,657.28. Following the completion of the sale, the chief financial officer now directly owns 18,122 shares in the company, valued at approximately $2,889,734.12. The disclosure for this sale can be found here. In the last three months, insiders sold 222,968 shares of company stock worth $34,980,922. 0.90% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in LH. Teachers Advisors LLC raised its position in Laboratory Corporation of America Holdings by 139.9% in the first quarter. Teachers Advisors LLC now owns 445,372 shares of the medical research company’s stock valued at $63,898,000 after purchasing an additional 259,709 shares during the period. Ngam Advisors L.P. raised its position in Laboratory Corporation of America Holdings by 8.7% in the first quarter. Ngam Advisors L.P. now owns 18,181 shares of the medical research company’s stock valued at $2,608,000 after purchasing an additional 1,454 shares during the period. MARSHALL WACE ASIA Ltd acquired a new position in shares of Laboratory Corporation of America Holdings in the first quarter worth $4,481,000. Marshall Wace North America L.P. acquired a new position in shares of Laboratory Corporation of America Holdings in the first quarter worth $4,481,000

Several other brokerages have also recently weighed in on LH. Craig Hallum restated a buy rating and set a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a sell rating to a hold rating in a report on Thursday, July 27th. Barclays PLC boosted their target price on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an overweight rating in a report on Thursday, July 27th. Jefferies Group LLC restated a hold rating and set a $170.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Wednesday, September 13th. Finally, ValuEngine upgraded Laboratory Corporation of America Holdings from a hold rating to a buy rating in a report on Wednesday, September 6th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Laboratory Corporation of America Holdings has an average rating of Buy and an average target price of $170.31.

Shares of Laboratory Corporation of America Holdings (LH) traded down 0.05% during midday trading on Tuesday, reaching $149.65. The company’s stock had a trading volume of 94,192 shares. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22. The firm has a market cap of $15.23 billion, a price-to-earnings ratio of 20.96 and a beta of 0.92. The stock’s 50 day moving average price is $153.32 and its 200 day moving average price is $148.94.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The business had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.36 EPS. Analysts predict that Laboratory Corporation of America Holdings will post $9.52 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/10/18/laboratory-corporation-of-america-holdings-lh-given-hold-rating-at-robert-w-baird.html.

In other Laboratory Corporation of America Holdings news, CEO David P. King sold 44,687 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $156.86, for a total value of $7,009,602.82. Following the sale, the chief executive officer now owns 258,753 shares of the company’s stock, valued at $40,587,995.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Glenn A. Eisenberg sold 5,968 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total value of $951,657.28. Following the completion of the sale, the chief financial officer now directly owns 18,122 shares in the company, valued at approximately $2,889,734.12. The disclosure for this sale can be found here. In the last three months, insiders sold 222,968 shares of company stock worth $34,980,922. 0.90% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in LH. Teachers Advisors LLC raised its position in Laboratory Corporation of America Holdings by 139.9% in the first quarter. Teachers Advisors LLC now owns 445,372 shares of the medical research company’s stock valued at $63,898,000 after purchasing an additional 259,709 shares during the period. Ngam Advisors L.P. raised its position in Laboratory Corporation of America Holdings by 8.7% in the first quarter. Ngam Advisors L.P. now owns 18,181 shares of the medical research company’s stock valued at $2,608,000 after purchasing an additional 1,454 shares during the period. MARSHALL WACE ASIA Ltd acquired a new position in shares of Laboratory Corporation of America Holdings in the first quarter worth $4,481,000. Marshall Wace North America L.P. acquired a new position in shares of Laboratory Corporation of America Holdings in the first quarter worth $4,481,000. Finally, Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of Laboratory Corporation of America Holdings by 2.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 9,853 shares of the medical research company’s stock worth $1,414,000 after acquiring an additional 210 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply